U.S. Biopharmaceutical Third Party Logistics Market Demand, Growth, and Forecasts To 2028

U.S. Biopharmaceutical Third Party Logistics Industry Overview

The U.S. biopharmaceutical third party logistics market size was valued at USD 36.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2021 to 2028.

The market is majorly driven by the launch of innovative biopharmaceutical products including cell & gene therapies that are creating more demand for cold chain storage, transport & distribution solutions. Moreover, 3PL service providers are also investing in technology due to fluctuating demand, capacity problems, and ongoing disruptions owing to the COVID-19 pandemic. The pandemic has led to restrictions on air travel & disrupting the airfreight market & delaying of supply of health products including vaccines to many countries. In the initial months of the pandemic, all the existing airfreight rates were suspended with UNICEF registering rate rises by as much as 500% but stabilizing at between 150 to 250%.

Gather more insights about the market drivers, restrains and growth of the U.S. Biopharmaceutical Third Party Logistics Market

U.S. biopharmaceutical third party logistics market size, by supply chain, 2018 - 2028 (USD Billion)

The COVID-19 pandemic has uncovered vulnerabilities within the supply chains, including the risk of just-in-time inventory & the likely benefits of relocating production near to the consumption point. A study looked at areas most impacted by the pandemic for shippers that comprises international transportation & logistics (43%), sourcing & procurement (30%), and manufacturing (24%). The third-party logistics market was largely impacted by labor & workforce management (33%), manufacturing (24%), and international transportation & logistics (23%).

The pandemic has also enhanced the demand within the cold chain. Maximum shippers expect the demand for cold chain capacity to rise over the next three years. Hence, most third-party providers have speeded up their growth plans, thus increasing their need for more cold chain capacity.

In addition, the companies are also playing a key role in the pandemic to meet the growing demand. For instance, McKesson’s deep expertise in the healthcare supply chain is playing an important role in delivering medical supplies & pharmaceuticals to customers & patients during critical times. This comprises supporting the U.S. government as a centralized distributor of the COVID-19 vaccines and the ancillary supply kits required to administer them.

Browse through Grand View Research’s Medical Devices Industry Research Reports.

  • Cold Chain Market – The global cold chain market size was valued at USD 210.49 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2021 to 2028.
  • Workforce Management Market – The global workforce management market size was estimated at USD 6.1 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 10.0% over the forecast period.

Market Share Insights

  • March 2021: FedEx Express announced that it has started shipping the newly approved vaccines for COVID-19 to dosing centers all over the U.S. on behalf of McKesson Corporation.

Key Companies profiled:

Some prominent players in the U.S. biopharmaceutical third party logistics market include

  • FedEx.
  • DHL International GmbH
  • SF Express
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corporation
  • DB Schenker
  • KUEHNE + NAGEL
  • Kerry Logistics Network Ltd.
  • Agility

Order a free sample PDF of the U.S. Biopharmaceutical Third Party Logistics Market Intelligence Study, published by Grand View Research.

Comments are closed